Form 8-K - Current report:
SEC Accession No. 0001193125-25-168096
Filing Date
2025-07-29
Accepted
2025-07-29 17:01:52
Documents
12
Period of Report
2025-07-29
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d927864d8k.htm   iXBRL 8-K 24066
  Complete submission text file 0001193125-25-168096.txt   137727

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20250729.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20250729_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20250729_pre.xml EX-101.PRE 11266
14 EXTRACTED XBRL INSTANCE DOCUMENT d927864d8k_htm.xml XML 3646
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 251162758
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)